Business Context and Reporting Period
Company: MiNK Therapeutics, Inc. (INKT)
Filing Type: Form 8-K (Current Report)
Report Date: August 13, 2026
Reporting Period: Quarter ended June 30, 2026
Context: The filing serves to announce the financial results for the second quarter of 2026. The detailed results are contained in a press release furnished as Exhibit 99.1.
Key Financial Metrics
The provided text is a cover sheet for the Form 8-K and does not contain specific financial data. The following metrics are not present in the source text:
- Revenue
- Net Profit/Loss
- Cash Flow
- Profit Margins
- Debt Levels
- Liquidity Position
Note: Specific values for these metrics are not provided in the filing text; they are referenced as being available in the attached press release (Exhibit 99.1).
Material Changes
The filing text does not provide specific data regarding material changes in financial performance compared to the prior comparable period. It only confirms the announcement of results for the quarter ended June 30, 2026.
Guidance, Outlook, and Risks
Management Commentary: The filing indicates that management has issued a press release regarding the results, but the text of that commentary is not included in this document.
Guidance and Outlook: No forward-looking guidance or outlook is provided in the text of this Form 8-K.
Risks and Contingencies: No specific risks or contingencies are detailed in this filing text.
Unusual Items: No unusual items are described in the provided text.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated August 13, 2026) for actual revenue, cash burn, and net loss figures.
- Verify the company's cash runway and liquidity position as disclosed in the full press release.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the full announcement.
- Confirm if the company provided updated full-year 2026 guidance in the press release.